

coronavirus 2 (SARS-CoV-2). Clinical and laboratory predictors may identification of patients at risk of mortality and guide treatment. To analyze laboratory abnormalities in patients with COVID-19 and define which parameters affect mortality and hospitalization **Methodology:** This retrospective study was conducted on 101 patients diagnosed with COVID-19. Demographic characteristics, laboratory parameters including complete blood count (CBC) parameters, biochemical tests, coagulation parameters, duration of hospitalization and final status (discharge or death) were recorded **Results:** Comparisons were made of survivors and non-survivors at the end of follow up period. Multivariate analysis showed mean platelet volume (MPV), platelet distribution width (PDW) and lactate dehydrogenase (LDH) to be significant predictors of mortality. The cut-off value of the hospitalization period was found to be 10 days, so patients were divided into two groups. In the multivariate models, no significant independent parameter was observed for the prediction of hospitalization duration. **Conclusion:** The results of the current study demonstrated that MPV, PDW and LDH were significant independent variables for the prediction of mortality. As SARS-CoV and SARS-CoV-2 are known to use the same receptor, there may be a similar structure and receptor for mutant variants and the first variant, so these predictive parameters can be considered to be as effective in mutant variants.

<https://doi.org/10.1016/j.htct.2021.10.979>

## OP 12

### AN UNUSUAL SURVIVING HISTORY: MULTISYSTEM INVOLVEMENT UNTIL ADULT LIFE WITH NIEMANN PICK TYPE B

Özden ÖZLÜK<sup>1</sup>,  
Metban GÜZEL MASTANZADE<sup>1</sup>,  
Beyza ŞEN OLUK<sup>1</sup>,  
Sevgi KALAYOĞLU BEŞİŞİK<sup>1</sup>,  
Bezirgen BALLYEV<sup>2</sup>

<sup>1</sup> Istanbul Medical Faculty, Hematology

<sup>2</sup> Istanbul Medical Faculty, Cardiology

**Objective:** Niemann-Pick disease (NPD) occurs with the storage of lipids including sphingomyelin and cholesterol due to acid sphingomyelinase deficiency. Based on genetic cause and clinical picture NPD are divided in four main types. The type B is called as non-neuronopathic variant in which many patients may survive several decades. Infiltration by lipid-laden foam cells of tissues contribute to life-threatening complications. We here present a case who has been diagnosed as having NPD in the adulthood. **Case report:** A 46-year-old male patient with peripheral edema and dyspnea and abdominal distention was investigated. He has a medical history of aortic and tricuspid valve regurgitation with severe pulmonary hypertension, decreased ejection fraction as 35% and ascending aortic aneurysm on 30 years old. He experienced three years later ascending aortic replacement and aortic valve replacement. He developed dyspnea, bleeding gums, and alveolar hemorrhage was diagnosed on 40s. **Methodology:** Pancytopenia associated massive splenomegaly and hepatomegaly contribute reassessment of the disease. Bone marrow revealed moderate

hypercellularity T lymphocytosis, focal mild dysplastic changes, and mild reticulin fiber increase. No cytogenetic abnormality and PNH clone was detected. He had developed congestive heart failure and massive proteinuria. Also he had medically controlled hyperlipidemia and interstitial lung disease. **Results:** A storage disease investigation was started. Plasma Chitotriosidase was found to be increased and leukocyte sphingomyelinase activity was decreased. A genetic screening for NPD revealed homozygote (SMPD1 p.V36A (c.107T> C) (rs1050228) and heterozygote G508R (c.1522G> A) (rs1050239). NPD type was diagnosed with probable kidney involvement and cardiac cirrhosis. Supportive treatment was decided. He succumbed in a short time on sepsis attack unfortunately. **Conclusion:** NPD type B is a rare storage disease. It is a multisystemic disease characterized by its clinical variability and could be overlooked until adulthood life with various differential diagnosis option. It should be considered.

<https://doi.org/10.1016/j.htct.2021.10.980>

## OP 13

### LEWIS C IN BREAST CANCER PROGRESSION

Нина Гадеская

ФГБУЗ МСЧ 174 ФМБА

**Case report:** Lewis C in breast cancer progression N.A. Gadetskaya<sup>1</sup>, N.N. Tupitsyn<sup>2</sup>, N.V. Bovin<sup>3</sup>, Udalova Ya.A.<sup>11</sup> At the moment of receiving these data - FSBU "Blokhin national cancer research center" of the Russian Ministry of Health, Moscow, Russia<sup>2</sup> FSBU "Blokhin national cancer research center" of the Russian Ministry of Health, Moscow, Russia<sup>3</sup> Yu.A. Ovchinnikov and M.M. Shemiakin Institute of Bio-organic chemistry of Russian Academy of Sciences, Moscow, Russia Exact evidences on the role of natural IgM antibodies in anti-tumor immune surveillance were proved by German team of scientists (Vollmers H.P. et al.) Binding of those antibodies to tumor cells leads in many cases to malignant cell death via lipoapoptosis. In 1994, P.D. Rye & R.A. Walker produced monoclonal IgM antibody LU-BCRU-G7 against breast cancer-associated glycoprotein. In early breast cancer, expression of this marker was seen in a group of patients with poor prognosis. Antibody recognized disaccharide Galβ1-3GlcNAc or LewisC (LeC), blood group H1-antigen precursor. We have studied glycan expression on tumor cells and antiglycan antibodies in more than 240 breast cancer patients. Immunohistochemical study in 89 cases of early breast cancer (pT1-2 N0 M0) revealed antigen expression in 57% of cases. Expression of LeC was significantly more frequent in tumors of larger sizes (> 3 cm): 85,0% vs 48,5% (p=0,004). Expression of LeC was much more frequent in breast cancers in which lung metastases were noticed in patient's follow up (more than 1 year) after operation (p=0,047). In LeC positive cases shorter (p < 0,1) DFS (disease-free survival) was noted, differences in DFS being near significant (p=0,05) in malignancy grade 3 and in moderate or prominent lymphoid infiltration (p=0,02), as well as long (> 4 years) patient's follow up. That data confirmed the note of Rye and Walker on poor prognosis of early LeC-positive breast cancer. In 67% of breast cancer patients small